Search
for
Sort by
Research 361–390 of 639
- Exosomes as a novel pathway for regulating development and diseases of the skin (Review)
- Rat steroid 5α-reductase kinetic characteristics: Extreme pH-dependency of the type II isozyme in prostate and epididymis homogenates
- Ritlecitinib: First Approval
- Clinical Aspects and Spectrum of Illness of TSS: Overview
- THE DISEASE SPECTRUM, EPIDEMIOLOGY, AND ETIOLOGY OF TOXIC-SHOCK SYNDROME
- Interventions for nail psoriasis
- Guidelines for the Use of Acitretin in Psoriasis
- Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology
- Epigenetic regulation in adult stem cells and cancers
- The mechanism of activated platelet‐rich plasma supernatant promotion of hair growth by cultured dermal papilla cells
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Interpretation of Laboratory Data and General Physical Examination by Pharmacists
- Episodic Neuropathic-Like Musculoskeletal Pain Associated With Ritlecitinib Therapy in Alopecia Universalis: A Case Report
- Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review
- Lipid nanocarriers as innovative strategies for hair regrowth
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Comparative safety profiles of baricitinib and tofacitinib in the treatment of adult alopecia areata: a pharmacovigilance study based on the FAERS database
- Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Baricitinib in the Management of Severe Alopecia Areata: A Report of Two Cases With Sustained Clinical Response
- Satoyoshi Syndrome: Difficult to find or treat?
- Neuroimaging Findings in Congenital Biotinidase Deficiency: A Case Report
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Journal of Population Therapeutics and Clinical Pharmacology
- Treatment of alopecia areata with JAK inhibitors: a review of the literature
- A 25-year-old female with a variable presentation of MCTD-A case report
- Secondary Adrenal Insufficiency : A Case Report
- Reporting on Adverse Clinical Events